The rule uses the hazard ratio of a time to event outcome such as all-cause mortality or event-free survival and indicates stopping the trial for safety concerns if the hazard ratio is nominally significant at a pre-specified level.
← all excerpts
Data monitoring committees for clinical trials evaluating treatments of COVID-19.
1
—
—